AbCellera Biologics Inc.

General ticker "ABCL" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.0B (TTM average)

AbCellera Biologics Inc. follows the US Stock Market performance with the rate: 48.3%.

Estimated limits based on current volatility of 2.3%: low 3.45$, high 3.61$

Factors to consider:

  • Total employees count: 600 (+2.4%) as of 2024
  • US accounted for 9.4% of revenue in the fiscal year ended 2024-12-31
  • Top business risk factors: Fluctuating operating results, Economic downturns and volatility, Regulatory and compliance, Supply chain disruptions, Market competition
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [2.66$, 6.15$]
  • 2026-12-31 to 2027-12-31 estimated range: [2.46$, 5.78$]

Financial Metrics affecting the ABCL estimates:

  • Positive: with PPE of -7.2 at the end of fiscal year the price was neutral
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -12.37 <= 0.01
  • Positive: Investing cash flow per share per price, % of 8.27 > -0.63
  • Positive: Shareholder equity ratio, % of 74.80 > 64.29
  • Positive: Interest expense per share per price, % of 0 <= 0.01

Similar symbols

Short-term ABCL quotes

Long-term ABCL plot with estimates

Financial data

YTD 2023-12-31 2024-12-31 2025-12-31
Operating Revenue $38.02MM $28.83MM $75.13MM
Operating Expenses $275.23MM $343.60MM $292.23MM
Operating Income $-237.21MM $-314.77MM $-217.10MM
Non-Operating Income $63.18MM $114.37MM $39.51MM
R&D Expense $175.66MM $167.26MM $186.83MM
Income(Loss) $-174.03MM $-200.40MM $-177.59MM
Taxes $-27.63MM $-37.54MM $-31.18MM
Profit(Loss)* $-146.40MM $-162.86MM $-146.41MM
Stockholders Equity $1,152.32MM $1,056.08MM $1,141.36MM
Inventory $1.11MM $0.00MM $6.34MM
Assets $1,488.09MM $1,360.55MM $1,356.95MM
Operating Cash Flow $-43.88MM $-108.56MM $-131.29MM
Capital expenditure $77.51MM $78.40MM $42.77MM
Investing Cash Flow $-221.11MM $121.41MM $87.75MM
Financing Cash Flow $10.36MM $12.77MM $14.08MM
Earnings Per Share** $-0.51 $-0.55 $-0.49

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.